Johnson & Johnson Stock (JNJ) News Today: RBC Raises Target to $240 as FDA Actions and Talc Verdict Shape the 2026 Outlook
CAs of Wednesday, December 17, 2025, Johnson & Johnson (NYSE: JNJ) is back in focus for investors looking for a “defensive” large-cap healthcare stock—while also weighing two forces that can move JNJ shares quickly: drug pipeline catalysts and talc litigation